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Abstract 45 
Over the last two decades, increased interest of scientists to study bone marrow adiposity 46 
(BMA) in relation to bone and adipose tissue physiology has expanded the number of 47 
publications using different sources of bone marrow adipose tissue (BMAT). However, each 48 
source of BMAT has its limitations in the number of downstream analyses for which it can be 49 
used. Based on this increased scientific demand, the International Bone Marrow Adiposity 50 
Society (BMAS) established a Biobanking Working Group to identify the challenges of 51 
biobanking for human BMA-related samples and to develop guidelines to advance 52 
establishment of biobanks for BMA research. BMA is a young, growing field with increased 53 
interest among many diverse scientific communities. These bring new perspectives and 54 
important biological questions on how to improve and build an international community with 55 
biobank databases that can be used and shared all over the world. However, to create 56 
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internationally accessible biobanks, several practical and legislative issues must be addressed 57 
to create a general ethical protocol used in all institutes, to allow for exchange of biological 58 
material internationally. In this position paper, the BMAS Biobanking Working Group 59 
describes similarities and differences of patient information (PIF) and consent forms from 60 
different institutes and addresses a possibility to create uniform documents for BMA 61 
biobanking purposes. Further, based on discussion among Working Group members, we report 62 
an overview of the current isolation protocols for human bone marrow adipocytes (BMAds) 63 
and bone marrow stromal cells (BMSCs, formerly mesenchymal (1)), highlighting the specific 64 
points crucial for effective isolation. Although we remain far from a unified BMAd isolation 65 
protocol and PIF, we have summarized all of these important aspects, which are needed to build 66 
a BMA biobank. In conclusion, we believe that harmonizing isolation protocols and PIF 67 
globally will help to build international collaborations and improve the quality and 68 
interpretation of BMA research outcomes. 69 
1 Introduction 70 
Over the last two decades there has been an increased interest by researchers to study bone 71 
marrow adipose tissue (BMAT) in relation to bone and adipose tissue physiology, which 72 
expanded the number of publications in the literature. Researchers have used different sources 73 
of BMAT to address the major questions in the bone marrow adiposity (BMA) field including: 74 
1) What is the role of BMAT and how does its function change in different physiological and75 
pathophysiological conditions compared to white or brown adipose tissues? and 2) How do we 76 
employ bone marrow adipocytes (BMAds) and bone marrow stromal cells (BMSCs) to enrich 77 
our knowledge about BMA? However, the methods used to isolate BMAT, BMAds and 78 
BMSCs, and the anatomical site(s) from which these are obtained, may influence their 79 
biological properties and the downstream analyses for which they can be used reliably. BMA 80 
is a young field that has recently received increasing attention among numerous scientific 81 
communities (2-6). The goal of this BMA biobanking position paper is to make protocols 82 
accessible for all interested researchers and to support researchers in designing their biobanks, 83 
sharing their samples and expertise to accelerate progress in BMA research. By facilitating the 84 
exchange of knowledge and biological samples, we aim to enhance BMA research worldwide. 85 
The BMA biobanking initiative was formed based on discussions among scientists involved in 86 
the International Bone Marrow Adiposity Society (BMAS), who created a BMAS Working 87 
Group (WG) focused on a need to coordinate biobanking activities in the field; develop 88 
guidelines and steps to advance establishment of biobanks for BMA research; and to enhance 89 
transparency about differences in BMA-related protocols used among the growing BMA 90 
research community.  Our Biobanking WG identified currently used collection procedures 91 
related to BMAT, BMAds and BMSCs isolated from bone marrow (BM) aspirates, BM plasma 92 
and bone tissues. Since samples might be shared among international collaborators, it is critical 93 
to consider aligning procedures as much as possible for all sites participating in BMA research, 94 
and where access to samples and data will be subject to the strictest scientific and ethical 95 
scrutiny. The WG realizes that this is currently impossible to achieve, but as first attempts 96 
towards harmonization for biobanks have been successfully employed to access cross-97 
institutional data (7), we aim to report here on the uniformities and discrepancies between 98 
protocols and storage of materials related to BMA. Our effort is in line with the recently 99 
published BMAS guidelines on nomenclature, abbreviations and units (1), as well as data 100 
reporting guidelines and methodological standards (8), produced by the BMAS working groups 101 
on Nomenclature and Methodologies, respectively. 102 
Ethical, legal and social issues are complex, affect many biobanking aspects, and have not been 103 
fully resolved by the scientific community. In this review, we will also address guidelines in 104 
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regard to BMA-related biobanking issues, such as informed consent, and compare differences 105 
in biobanking procedures and institutional patient information forms (PIFs). 106 
The main goal, therefore, of this paper is to describe the current uniformities and discrepancies 107 
for the collection, use, storage and monitoring of BMA-related samples. A stepwise approach 108 
going from medical ethical approval through collecting and storing samples to the 109 
characterization and analysis of BMA-related samples is depicted in Figure 1. Although we 110 
are still far from a global harmonization of protocols, achieving this would greatly enhance the 111 
quality and interpretation of BMA-associated outcomes and increase the impact of BMA 112 
research. In fact, broad consent for future research may facilitate harmonization as well and, as 113 
it is ethically valid, this should be recommended for biobank research (9). 114 
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1 Introduction to Biobanking 133 
Biological collections and collection-based science was first described by Carl von Linné in 134 
the 18th century when he proposed the first system of classification for all biological species on 135 
earth (10, 11). The term “biobank” was used for the first time by Loft and Poulsen in 1996 136 
when they suggested the use of human biological material to study a risk factor in cancer (12). 137 
Ever since, the field of biobanking has been expanding and it is now a fundamental and 138 
indispensable infrastructure for global health research (13-15). However, a BMA biobank has 139 
not yet been created. In general, a “biobank” includes large collections of biological samples 140 
such as DNA, cells, solid tissues or blood samples (16, 17) , which are often stored for a long 141 
period of time and used only once a certain number of samples have been collected. They can 142 
also be processed, distributed, and used immediately. Samples are used by a variety of research 143 
projects and end-users, for example in population-based cohorts for diagnostic or interventional 144 
clinical trials, for medical needs/treatments, or for basic researchers validating their findings in 145 
human samples. Biobanks can be hospital-, government- or academic-based; networked or 146 
more isolated; and for profit or non-profit organizations (16-18). The population-based UK 147 
Biobank, between 2006 and 2010 collected biological samples from 500,000 volunteers 148 
without specific inclusion/exclusion criteria. Its aim was to investigate the influence of 149 
individual genetic susceptibility and exposure to external factors (19). In contrast, disease-150 
oriented biobanks collect disease-specific specimens and non-diseased controls (20). 151 
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Therefore, the definition of “biobank” varies greatly due to different types and 152 
components/purpose of biobanks, and because many biobanks evolved in a local and 153 
decentralized manner (13, 17, 21). Different national regulations established by local 154 
governance such as ethical guidelines or data protection provoke heterogeneity with regard to 155 
biobanking; however, for sharing biological samples with the scientific community, standard 156 
procedures for harmonization are required (21). Major advantages of the centralization of 157 
processing and standardization are the reduction of costs, increased throughput, and improved 158 
accuracy of sample handling and picking (22). The Organization for Economic Cooperation 159 
and Development (OECD) recommendations on Human Biobanks and Genetic Research 160 
Databases (HBGRD), published in 2009, provide guidelines for the establishment, 161 
management, governance, operation, access, use and discontinuation of human biobanks and 162 
genetic research databases (23). The structural key elements for sustainable international 163 
scientific infrastructure are named Biological Resource Centers (BRCs) as defined by the 164 
OECD (24). In addition, the International Organization for Standardization publishes standards 165 
for biobanks and bio-resources in ISO 20387 (ISO 20387:2018 “Biobanking – General 166 
requirements for biobanking”) to harmonize the biobank procedures. It also provides a 167 
professional environment for handling not only biological samples but also animal, plant and 168 
microorganism resources. Besides quality control of samples, ISO 20387: 2018 also includes 169 
validation of methods and competences of personnel (21, 25). In addition to the biobank 170 
infrastructure itself, the term “biobank” also covers bioethical and legal issues including 171 
ownership, informed consent and privacy – anonymization (17). 172 
2 Informed consent form for BMA-related research 173 
2.1 Providing information before donation 174 
Informed consent is a first, critical step in any tissue donation.  Informed consent is not merely 175 
a disclosure form confirmed by a signature, it must also promote participant’s understanding 176 
of the research project and emphasize the voluntary nature of participation (26). The informed 177 
consent form consists of two parts: the informed consent certificate (containing approval of 178 
participant) and the Patient Information Form (PIF). Generally, the patient/donor is presented 179 
with the consent form after they have familiarized themselves with the PIF (see below).  180 
However, some institutions administer both consent form and the PIF simultaneously. The 181 
consent form should state that the patient had time and the opportunity to consider the 182 
information contained in the PIF, to ask questions, and obtain satisfactory answers to those 183 
questions. The consent form should explicitly state that the risks and benefits of the study have 184 
been clearly explained to the participant. The forms can be broad or specific to BMA research; 185 
the advantage of a broad consent form is that the collected samples can be used for a number 186 
of research projects that do not have to be specified at the time of consent. This breadth may 187 
be particularly useful for BMA research, which spans numerous other research fields. On the 188 
other hand, formulating the consent form specific for BMA research might make it easier for a 189 
donor to agree to participate, as they will know precisely what their samples will be used for. 190 
In fact, there is not yet a consensus on the policy regarding consent issues (27). The potential 191 
use of biobanked samples for translational work that may involve industrial collaborations and 192 
eventual commercial applications should also be discussed, as this may require explicit 193 
consent. For this reason, some countries have opted to include on their informed consent 194 
template a clause specifying that the patient waives future commercial rights. 195 
Participants should realize that they are signing the consent to allow the storage and use of 196 
their specific biospecimens and any data resulting from the research using those specimens. 197 
Thus, it should be clear that only approved research studies can gain access to a donor’s de-198 
identified data and samples. Studies that utilize the specimens and/or data need to receive 199 
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prior scientific and ethical approval by the relevant committees, such as the IRB (Institutional 200 
Review Board), and they need to fit within the general requirements of the biobank and align 201 
with the consent form. 202 
2.2 Deidentification as prerequisite before consenting 203 
Deidentification of data is a critical component of any research study involving human 204 
subjects. The procedures that will be used to protect the privacy and confidentiality of the 205 
subject’s data need to be clear to the potential donor prior to consenting. Unfortunately, 206 
biobank participants are not always made aware of the confidentiality risks associated with 207 
participation, which is a major ethical concern (28). Therefore, the donor needs to clearly 208 
understand how records will be secured, who will have access to the identifiable data, and 209 
whether names or ID numbers will be used. The procedure for securing the file linking the 210 
codes to individual subjects needs to be explained and participants should be informed about 211 
these issues while discussing the informed consent (29). Not all institutions include a Data 212 
Privacy Statement as part of their consenting protocol, and it is critical that this procedure is 213 
standardized across all institutions participating in BMA biobanking. 214 
2.3 Possibility of withdrawal from a clinical study 215 
The consent form should state that the donor can withdraw from the study at any point and 216 
the acceptable ways to withdraw (e.g., email, phone call, letter) should be indicated.  It 217 
should be clearly explained that upon withdrawal, identifiable samples and the associated 218 
data will be destroyed, unless the data have already been used for research. This is in line 219 
with the guidelines of the International Bioethics Committee (UNESCO) stating that handling 220 
of data and biological samples should follow the wishes of the donor unless they are 221 
irretrievably unlinked, making it impossible to do so (30). Accordingly, the consent form 222 
should indicate that the code that enables re-linking the samples with personal information 223 
will be deleted and only the signed consent form and a copy of the withdrawal letter will be 224 
kept as a record. These steps will prevent information about the donor contributing to further 225 
research and analyses. 226 
3 Patient Information Form as basis for BMA-related biobanking and ethics 227 
discusison 228 
Many research institutes have templates for patient information and informed consent forms, 229 
and The Research Ethics Review Committee of WHO provides general templates and 230 
recommendations that can be adapted to specific needs (31). Within a PIF, the participant 231 
taking part in the study should be accurately informed about the planned study, what material 232 
will be collected and how it will be stored and used for research purposes. Although not every 233 
detail of the study has to be provided, the donor should have a rough idea of what will be done 234 
with his/her material and know that the collected samples will be handled with the utmost care 235 
and adherence to the various regulations, including those according to the General Data 236 
Protection Regulation (GDPR). The consent process can be improved by using clear and simple 237 
language in the documents (26, 32). Discussions between investigator and patient are 238 
encouraged to improve participant comprehension and ensure consent to participate (32). 239 
Below is a list of items that the WG believes should be mentioned in the PIF and which will 240 
be elaborated upon briefly, point by point (Table 1). 241 
3.1 Positive disadvantages or risks and benefits of donation 242 
With every medical treatment or procedure there is some risk involved. Thus, the sample 243 
procurement procedure should be sufficiently risk-assessed and communicated to the donor. 244 
Standard donation through tissue biopsies or blood drawing constitutes minimal risk, while 245 
bone marrow biopsies or aspirations are more invasive and have an increased risk of various 246 
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complications that need to be specified. Complications are rare, but as with any procedure 247 
involving a tissue biopsy, there is a small risk of bleeding and/or bruising from the sampling 248 
site. Moreover, there are descriptions of rare cases of deep tissue infections, severe internal 249 
bleeding or bone fracture associated to the bone marrow biopsy/aspiration procedure.  In the 250 
case of sampling as a byproduct during knee/hip surgery, there are no other risks beyond those 251 
usually associated with surgery. In all cases, there should be a lead doctor or research nurse 252 
involved to answer questions surrounding the tissue/cell collection. Moreover, donors should 253 
be informed about the potential risk of not being able to use the material, for example by 254 
unanticipated loss or low quality of the material obtained. 255 
Benefits also have to be addressed towards the donor, with the general message that no direct 256 
benefits (e.g. financial or material) can be obtained from participating in a study. Having said 257 
that, being a donor contributes to the general understanding of diseases or tissues, such as 258 
BMAT, which may lead to future development of new, effective treatments, and thereby may 259 
benefit patients. In addition, healthy control donors are often compensated for their 260 
involvement in a research study in the form of a small fee for the incremental inconvenience, 261 
burden or risk associated to dedicated tissue collection, as opposed to the often-uncompensated 262 
donation of residual tissue obtained upon routine medical procedures (33-35). Providing 263 
relevant background information about the goals of the study and the expected results is key 264 
and will increase participation rates. This will lead to more impactful studies with more reliable 265 
conclusions on BMA-related outcomes. 266 
3.2 Constraints and safeguards of biobanking 267 
For any clinical study to start, two critical steps are required. Firstly, approval of a medical 268 
ethical board is required within the institute where the study is conducted. When a study is 269 
multi-centered, there should be an additional approval from the cooperating institutes, but this 270 
could be partial or less stringent as long as the coordinating center has a full approval. 271 
Secondly, a valid, written consent is needed before the acquisition or use of the intended 272 
BMA-related sample or associated clinical data. By definition, the donor’s participation is 273 
always voluntary and he/she can always withdraw from the study. The participant will never 274 
have access to his/her own data as all data are anonymized. In fact, as soon as a sample is 275 
obtained, it should be fully deidentified through encoding in any biobank. None of the users 276 
employing the samples or analyzing data belonging to the study can trace back any of the 277 
material to any of the person-related data belonging to the donor. This is one of the primary 278 
requirements for any medical study involving patient or participant biomaterial and all effort 279 
should be taken to prevent any breach of confidentiality. 280 
3.3 Differences between institutional PIFs and biobanking procedures 281 
In preparation of this position paper, the BMAS Biobanking WG has scrutinized and 282 
compared PIFs derived from seven different institutes across Europe and the US. It became 283 
evident that there are differences regarding the various aspects described above, especially in 284 
the context of the actual content and the level of detail of the proposed research, but also with 285 
respect to which measures have to be taken to safeguard the anonymity of the participant in 286 
the study and the protection of the acquired data. We thus realized that there are many 287 
hurdles to overcome in an attempt to harmonize protocols and procedures across the globe. 288 
4 Biological materials relevant for BMA-related research 289 
The types of tissue/cell that will be collected for BMA-related studies are primarily driven by 290 
the sample accessibility. Bone and BM samples can often be obtained during invasive 291 
procedures, such as surgeries (joint replacement, amputations, open-heart or spinal surgery), 292 
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autopsies, bone marrow biopsies and bone marrow aspirates (8). The nature of the research 293 
depends on the surgery and biopsy type, which determines the anatomical site, patient 294 
characteristics (underlying pathology, age, sex, etc., as reviewed below), quantity and quality 295 
of sample, and transportation/storage capabilities. Other tissues, such as subcutaneous white 296 
adipose tissue (WAT) and venous blood, can also be collected in parallel, but only 297 
waste/discarded material, or small samples that cause minimal risk, should be used. 298 
Subcutaneous WAT is relatively easily obtained at the site of surgery and can be used as a 299 
reference for BMAT analyses, and serum/plasma can be assessed for relevant biomarkers, for 300 
example for metabolic function and bone remodeling (biochemical analyses). 301 
The presence of BMAds is variable depending on the surgery site but could be also due to 302 
patient heterogeneity (Figure 2). For example, as demonstrated from Magnetic Resonance 303 
Imaging analyses, the femoral head is expected to be more enriched for BMAds compared to 304 
the ilium, while the femoral or tibial diaphysis are expected to have even greater BMA than 305 
the femoral head (36). The pathophysiological context can also be a source of heterogeneity in 306 
BMAd development and phenotype, and can consequently influence the BMAd isolation, 307 
analysis, and study outcomes. Indeed, age, sex, lifestyle habits, metabolic status (e.g. obesity, 308 
diabetes, anorexia), medications (e.g. thiazolidinediones, glucocorticoid analogs, hormonal 309 
substitutive therapy, radio- or chemo-therapy) and the pathology underlying the orthopedic 310 
surgery (osteoporotic fractures, osteoarthritis, osteonecrosis, etc.) are conditions known to 311 
modify the BMAd component (as reviewed in (37-41)). Therefore, it is important to collect 312 
donor clinical characteristics, including age, sex, body mass index (BMI), medication history, 313 
and incidence of fractures in order to better define the heterogeneity of clinical material (Table 314 
1). 315 
In this context, it is very challenging to establish a harmonized “healthy” control set for 316 
biobanking as the definition of “healthy control” varies among different studies, depending 317 
on the clinical sampling, the aim and biological questions. The “healthy control” samples are 318 
ideally obtained by bone marrow biopsies and aspirates from healthy volunteer donors. Yet, 319 
as emphasized above, ilium may not represent the most reliable bone site to study BMAds. 320 
Orthopedic surgery of healthy patients (not diagnosed with BM diseases or necrosis) 321 
following trauma or amputation are an exception, while it is sometimes possible to get 322 
“healthy” samples considered as debris during surgery. In fact, this type of surgery currently 323 
delivers most of the “healthy” samples. Post-mortem sampling from organ donors can also be 324 
considered if the subsequent analyses (such as adipocyte histomorphometry) are compatible 325 
with a delayed processing; however, BMAd molecular characteristics are likely to be 326 
compromised in such post-mortem samples. It is the responsibility of the research team to 327 
clearly establish and describe the inclusion and exclusion criteria, which subsequently allows 328 
for categorization of “healthy” or “control” versus “study” group(s). Alternatively, a referent 329 
cell type (e.g. subcutaneous adipocytes, BMSCs from another bone site) isolated from the 330 
same patient can be used for comparisons when studying isolated BMAds. 331 
4.1 Choice of BMA relvant biological materials and their use 332 
Due to the various types of tissue and cell types relevant to BMA, the unclear definitions of 333 
cell populations and the relatively recent emergence of the field, the methodology behind 334 
collecting BMAT, BMAds and BMSCs is heterogeneous as recently reviewed (8). It is 335 
important, for all samples that have been collected, to specify if screenings have been 336 
performed for viral diseases (typically HIV, HBV and HCV), as in some countries a negative 337 
test is a prerequisite to allow usage of the samples in research facilities. So, for the future of 338 
biobanking it is important to keep track of these variables. 339 
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4.1.1 Operation specimens and autopsies 340 
A reliable method to obtain fresh BMA-relevant biological material is during orthopedic 341 
surgeries, such as knee and hip replacements, reconstructions, corrections and amputations. 342 
During these operations, a key part of the surgical procedure is removal of bone and bone 343 
marrow that is often discarded after the surgery. It is possible to recover this biological material 344 
for BMA-related research and biobanking. A good example is hip replacement surgery, where 345 
the femoral head and part of the trabecular bone cavity are removed and simply discarded, if 346 
not transferred to a bone bank as allograft material.  With these surgical specimens, it is possible 347 
to process samples for downstream detailed histology (see bone marrow biopsies) (Figure 2) 348 
or to isolate almost all desired adipocytic, stromal and hematopoietic bone marrow cell types; 349 
see also section 4.2. 350 
Post-mortem autopsies offer a unique opportunity to obtain BMA-relevant biological 351 
materials from several skeletal sites, and not only the classical sites undergoing orthopedic 352 
surgery or bone marrow biopsies. As mentioned earlier, these autopsies are useful only for 353 
simple adipocyte histology and histomorphometry, and ex vivo imaging by micro-computed 354 
tomography (µCT); they are not suitable for molecular analysis and cell isolation (unlike for 355 
fresh operation specimens and bone marrow biopsies). Nevertheless, histomorphometry and 356 
imaging of autopsy samples are still useful as they allow for analysis of the BM compartment 357 
to analyze the BMAd content, morphology and size (Figure 2A). High quality tissue may 358 
however be banked in the exceptional context of systematic bone tissue collection from post-359 
mortem organ donors. 360 
4.1.2 Bone marrow biopsies 361 
Transiliac bone biopsies obtained with a Meunier/Bordier trephine (inner diameter 5-8 mm) 362 
have for decades been the gold standard within bone research and diagnostics. These biopsies 363 
are obtained under a quite invasive procedure, usually performed under general anesthesia. 364 
For BMA-related research, it is sufficient to obtain iliac bone marrow biopsies with a 365 
Jamshidi trephine (inner diameter 3 mm, recommended length 2cm (42)); this is a much-less-366 
invasive procedure usually performed under local anesthesia, which also allows for collection 367 
of a bone marrow aspirate (Figure 2B). These 3-mm bone marrow biopsies are the gold 368 
standard in hematology research and diagnostics, and due to their less-invasive nature they 369 
are more justifiable from an ethical perspective. The usability of these biopsies is versatile for 370 
BMA-related research, as it is for surgery specimens. For BMA-related research by histology 371 
there is no need to embed the undecalcified specimens/biopsies in plastic, as done for 372 
classical bone histomorphometry. Instead, the specimens/biopsies can be fixed, decalcified 373 
and paraffin- or frozen-embedded. Ex vivo imaging by µCT or similar method can be 374 
performed before the specimens/biopsies are decalcified. The embedded specimens/biopsies 375 
are then usable not only for adipose histomorphometry (see autopsies), but also for more 376 
advanced molecular histology, like multiplex immunostaining, in situ hybridization, laser 377 
microdissection and spatial transcriptomics (8). This facilitates detailed analysis of BMAd 378 
spatial distribution, gene expression profile, and interaction with other cell types in the BM. 379 
4.1.3 Bone marrow aspirates 380 
BM aspirates are primarily taken from the iliac crest or femoral bone marrow biopsy 381 
(occasionally from femoral epiphyses) site, usually following the biopsy under local anesthesia. 382 
This is a less-invasive procedure and allows for relatively easy collection of BM fluid 383 
containing various cell types, including adipocytes (43-45). The BM aspiration procedure is 384 
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not necessarily familiar to the participant and the PIF should describe what happens during 385 
sampling on a step-by-step basis, including injection of the local anaesthetic into the location 386 
where the sample is to be taken from. BM aspirates are especially useful for the collection of 387 
various cell types, including a BMAd-enriched fraction (see section 5) and BMSCs (8). The 388 
cells can be directly cultured following collection, or they can be prepared for storage to be 389 
analyzed later. Typically, the different BMSC-related cultures are employed to study cell 390 
behavior, differentiation, marker expression and/or their interaction with other cell types 391 
(mimicking the situation in BM). BMAd-enriched fractions can be extemporaneously used or 392 
stored for further molecular and biochemical analyses. Although no cell type or tissue 393 
collection is involved, in vivo analyses of BM are increasingly available and provide a good 394 
source of information on BMA content, composition, spatial and temporal distribution (etc.), 395 
and it would be very helpful to compare these in vivo analyses to biobank data (8). 396 
4.1.4 Subcutaneous fat 397 
Subcutaneous fat can be collected at the surgery site and provides a rich source of adipocytes 398 
and Adipose tissue-Derived Stromal Cells (ADSCs, nomenclature according to (1)), that can 399 
be used for reference, for example for comparison with BMAds and BMSCs. 400 
4.1.5 Blood samples 401 
Venous blood can be collected in different ways depending on the research question but most 402 
often is stored in the form of serum (for measurement of biochemical parameters e.g. lipids, 403 
growth factors, hormones or plasma collected in the presence of anti-clotting agents (e.g. 404 
EDTA or Heparin) (for molecular analyses, chemistry, or cell culture). Quantification of 405 
metabolites in blood samples requires standardization of pre-analytical processing and rapid 406 
cooling down, as reviewed here (46-48).  If blood samples are obtained in the fasted state, it 407 
is also possible to investigate the level of bone resorption and formation using markers like 408 
P1NP, CTX, NTX and TRAcP, and link this to the (49). 409 
4.2 Isolated human primary BMAds and BMSCs 410 
BMAds are present scattered or more packed within the BM of different bones in humans 411 
(Figure 2). Accessibility of the BM cavity is obviously required to isolate BMAds, which 412 
restricts the bone sites available to obtain samples (i.e., BM biopsy sites, resected bone pieces 413 
and BM aspirates of long bones obtained during orthopedic surgery). So far, BMAds and 414 
BMSCs have been obtained from different locations including the femoral head (50, 51), the 415 
diaphyseal end of the femur or tibia (52), BM aspirates from the femur (53) and the iliac crest 416 
(54, 55)(Figures 2 and 4). 417 
Specific procedures for the collection of BMAds are relatively novel (see below), and in some 418 
cases freshly isolated BMAds may be needed for immediate analysis. However, BM fragments 419 
and BMSCs have been successfully collected and biobanked, followed by optimized 420 
characterization of the cryopreserved material (56, 57). 421 
The process of sampling is also variable and influences the quality of BMAd isolation. For 422 
example, for hip arthroplasty the femoral head is removed using a surgical saw and, prior to 423 
insertion of the artificial hip, the medullary canal is cleared using a reaming tool before 424 
aspiration of the BM. These steps are often done using electric saws and reamers, but non-425 
electric tools can also be used. Similarly, some electric reamers simultaneously aspirate the 426 
BM cavity, but aspiration can also be done manually, post-reaming, using a syringe and soft 427 
cannula. These different methods (i.e. electric vs non-electric) can affect the quality of BMAds 428 
as a result of differences in heat production and/or mechanical stress (51, 53, 58). 429 
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Thorough discussions with the surgeons are thus instrumental to determine the optimal 430 
processes and to adapt surgical techniques, when possible, for BMAT sampling. 431 
As previously encouraged (8), a detailed description of the source of BMAds is consequently 432 
required for biobanking purposes and study comparisons. Firstly, minimal information should 433 
state the original skeletal location, i.e. distal/proximal bone site, trabecular bone or BM 434 
(Table 2). Secondly, patient characteristics should be reported including the distribution by 435 
age, sex and BMI as well as the pathophysiological context, i.e. the presence of bone disease, 436 
osteo-articular disease, hematological disease, malignancies, and their related treatment. 437 
According to the studied questions, other specific parameters (such as BMI, metabolic status 438 
when relating to energetic metabolism perturbations for example) are also expected. Thirdly, 439 
how the original clinical sample is obtained (i.e., use of electric or non-electric surgical tools, 440 
use of digestion or other sample processing and any other relevant details) should also be 441 
described. 442 
5 Methodology of BMA-related cell isolation and analysis 443 
Various protocols for human BMSC isolation (55-57, 59-61) and, to a lesser extent, for BMAd 444 
isolation(50-54, 62-64) have been published. Isolated BMSCs are classically used in vitro to 445 
analyze their differentiation capacity into different lineages, to study BM cell interactions, to 446 
characterize progenitor markers, to analyze BMSC senescence and to compare their molecular 447 
and cellular characteristics to different sources of stem cells, including peripheral ADMSCs. 448 
Thus far, applications for isolated BMAds are devoted to characterizing their specific 449 
phenotype by comparison with extramedullary adipocytes, such as subcutaneous WAT 450 
adipocytes, using RNA analyses, proteomics or lipidomics. The downstream analyses, as well 451 
as the research context encompassing the biological questions, the clinical sampling and the 452 
type of comparative/referent samples, have to be taken into consideration for the choice of the 453 
isolation method. 454 
In this review we provide dedicated protocols for isolation of BMAds and/or BMSCs. As 455 
discussed within each section, the absence of other contaminant cells, the cell integrity and 456 
the cell yield determine the success of the method. Considering the great heterogeneity in 457 
patients and samplings, it is advised to file a small piece of the initial tissue for histological 458 
analysis (Figure 2). Besides, BMSCs can be obtained, though in small amount, during the 459 
BMAd isolation procedure. In addition, a floating lipid-loaded cell layer is often observed 460 
following the processing of BM aspirates or trabecular bone samples before any collagenase 461 
digestion (Figure 3A). This cell fraction most likely results from the surgical procedure that 462 
allows the release of BMAds that are loosely attached and contains both BMAds and 463 
contaminant cells from the hematopoietic and the stromal compartment. We suggest referring 464 
to this as a BMAd-enriched fraction (i.e. fraction that is obtained from BM but without 465 
collagenase digestion, as illustrated in Figure 3), which could be used for lipid analysis. Yet, 466 
this BMAd-enriched fraction should be used only after digestion and washing steps if pure 467 
BMAds have to be analyzed. This floating lipid-loaded cell layer is not to be confounded 468 
with the free lipid layer that results from spontaneous cell lysis upon excessive mechanical 469 
processing, excessive ambient temperature or handling time (Figures 3 and 4). 470 
5.1 Isolation of BMAds 471 
Various laboratories have already started working on BMAds isolated from BM aspirates, from 472 
femoral diaphysis (51-53, 64), from trabecular bone of the proximal femoral 473 
metaphysis/epiphysis (51), the femoral head (50, 62, 65), femoral BM fluid (62), the proximal 474 
tibia (52) or the iliac crest (54) (Figure 2). Within our working group, three protocols were set 475 
up and validated to isolate and purify BMAds, and accordingly, the critical steps to obtain pure 476 
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primary BMAds for different analyses are depicted here. These main steps are based on 477 
protocols commonly used for the isolation of adipocytes from peripheral WAT, which have 478 
been adapted from the initial work of Rodbell (66). Tissue digestion is commonly performed 479 
using collagenase to release BMAds from the extracellular matrix, which is mainly composed 480 
of collagen fibers (67). Indeed, if the study relies on a comparison between isolated BMAds 481 
and WAT adipocytes, a similar method based on collagenase digestion should be performed. 482 
However, this enzyme-based isolation is not required if the study focuses on characterizing 483 
only BMSCs. Within the following sections we describe how the clinical sample is obtained 484 
and provide a general protocol to process these samples with joined notes to discuss key 485 
aspects. The main differences between our three protocols relate to reagents, as highlighted in 486 
Tables 2 and 3. It is important to emphasize that each protocol has been tested and established 487 
separately. As combining reagents between the protocols has not been validated, it is 488 
recommended to strictly use the advised reagents for the selected protocol. 489 
5.1.1 Isolation and transport of samples 490 
As mentioned above, BMAds are isolated from femoral head, BM aspirates of femoral 491 
proximal metaphysis/diaphysis or trabecular bone from distal femoral epiphysis (Figure 4). 492 
The femoral head is removed with an electric bone saw and stored in buffer or processed 493 
immediately in the surgical theater and the bone fragments obtained by mechanical processing 494 
stored in transport buffer. To obtain BMAds from the femoral head (51, 65), the trabecular core 495 
is first exposed by bisecting the femoral head longitudinally using an electric bone saw. A 496 
sterile spoon spatula is then used to cut and scoop out ~1 cm3 portions of the trabecular bone 497 
from within the femoral head. The medullary cavity of the proximal femoral metaphysis and 498 
diaphysis is then cleared of trabecular bone by using a manual reaming tool, with a bone mallet 499 
used to drive the reamer into the medullary canal. To obtain BMAds from it, portions of 500 
trabecular bone are then removed from the reaming tool, washed and stored in buffer (51) 501 
(Figure 4A-B). 502 
To obtain BMAds from the proximal diaphysis, BM from this region is aspirated using a soft 503 
cannula attached to a manually operated syringe. The aspirate is then transferred to a sterile 504 
petri dish or specimen tube prior to washing and storing in buffer (51, 53, 64) (Figure 4A-B). 505 
To obtain trabecular bone from distal femoral epiphysis, 1 cm3 of cancellous bone square is 506 
taken in the center of the femoral epiphysis using adapted cold chisels after the first distal 507 
femoral cut during knee prosthetic surgery (Figure 2). 508 
As soon as the sample is harvested, it must be placed in transportation buffer (Table 3) and 509 
transferred to the laboratory in the quickest manner possible1,2,3. 510 
Notes: 511 
1-  Different buffers are used in our laboratories and the composition of these buffers is detailed512 
in Table 3. All these media should be at pH 7.4 (buffered with HEPES and/or bicarbonate) 513 
and contain inorganic salts and glucose as nutrients are needed to maintain tissue integrity. 514 
2- It is recommended to transport the sample at room temperature (~20°C) and to minimize515 
strong temperature changes. Yet, for some applications such as molecular analysis (RNA 516 
expression, protein or lipid content characterization), keeping samples at 4°C (on ice) can 517 
be advised as reported in (51). For biobanking purposes, the effect of transport/storage 518 
conditions on cell properties and on any post-isolation changes still remains to be tested. At 519 
the moment, we recommend documenting the transport/storage conditions for every sample. 520 
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3- Ideally the transportation should be achieved within 30-60 minutes since the reduction of521 
oxygenation and nutrient deprivation at the center of the sample may compromise tissue522 
integrity, as already reported for other adipose tissues (53, 64).523 
5.1.2 General protocol for BMAd isolation 524 
Reagents & Equipment: 525 
●digestion buffer with collagenase (composition in Table 2), pre-warmed at 37°C526 
●washing buffer (composition in Table 2), pre-warmed at 37°C527 
●shaking water bath at 37°C528 
●Polypropylene tubes4529 
●cell strainer (100 µm) or a Nylon mesh (porosity between 150 to 300 µm)530 
●classical instruments and lab pipets/tips531 
Notes: 532 
4- To limit the lysis of BMAds we recommend working only with plastic, because glass tubes533 
cause lysis of adipocytes. 534 
General protocol (Figure 4B-C)5: 535 
• Rinse the tissue several times in the transport buffer (Table 2) to remove tissue debris and536 
clotted pieces. 537 
• Mince the tissue in small pieces to facilitate digestion6 and add tissue pieces in the digestion538 
buffer7,8 containing collagenase9. 539 
• Digest the tissue at 37°C in a water bath under gentle shaking (from 120 to 200 rpm) with a 540 
careful and continuous monitoring of the incubation time10. 541 
• At the end of digestion11, filter the cell suspension, either on a cell strainer or a Nylon mesh542 
over a tube. The strainer or mesh should have a pore size of at least 100 µm, given the large 543 
size of adipocytes. 544 
• Add washing buffer to dilute the collagenase and to rapidly stop the collagenase action.545 
• Allow the adipocytes to then float in the filtered suspension either storing upright the tubes546 
or centrifuging (5min, 300 g). 547 
• Aspirate the infranatant and the cell pellet12.548 
• Wash 3 times the floating adipocytes by adding washing buffer and centrifuging for 5 min at549 
300 g to pellet contaminant cells13,14,15. 550 
• Collect the BMAds in this floating layer using a micropipette16 or by removing the remaining551 
washing buffer as much as possible following a short centrifugation step to pack the floating 552 
cells17. 553 
Notes: 554 
5- The isolation protocol is performed at room temperature with the exception of the digestion555 
step. Please be aware that in poorly temperature-controlled environments (for example in 556 
the summer months), BMAd viability may be considerably compromised. 557 
6- Unless the tissue is already partly dislocated, such as for the BM aspirates, the other tissue558 
types (e.g. cancellous bones) are then minced in small pieces to facilitate digestion. 559 
Cancellous bone from the femoral epiphysis or metaphysis is for example transferred in a 560 
small flat plastic dish and kept immersed in digestion buffer to be cut using a scalpel or 561 
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scissors to get pieces of ~5mm3. During cutting, the bone can be held in place using cutting 562 
clamp or forceps, as needed. 563 
7- The digestion is favored by an appropriate balance between the volume of digestion buffer564 
and the amount of tissue fragments. We recommend the use of two buffer volumes for each 565 
sample volume or, if preferred, 2 mL buffer per gram of tissue. 566 
8- Digestion buffer can vary from PBS, Dulbecco’s Modified Eagle’s Medium (DMEM) to567 
Krebs Ringer HEPES (KRH), highlighting the importance of a basic ionic strength (Table 568 
2). The presence of glucose may not be necessary during a short digestion duration but can 569 
be advised to minimize changes following transportation or when metabolic features of 570 
BMAds are studied. Importantly, the presence of fatty-acid-free Bovine Serum Albumin 571 
(BSA) at classical concentrations of 2 to 3% (w/v) is instrumental: BSA binds the released 572 
fatty acids and prevents their detergent action on cell membrane (68). 573 
9- Different collagenases can be used with yet a careful choice (Table 2). Indeed, collagenase574 
preparations differ between manufacturers and from batch to batch. Thus, our labs first 575 
check the efficiency of the collagenase batch they use and determine the collagenase 576 
amount and the digestion duration to obtain a BMAd suspension. BMAds are more fragile 577 
and loosely associated compared to adipocytes from WAT. Thus, digestion time for BM 578 
tissue can be reduced; however, it remains unclear how differences in digestion duration 579 
affect the final properties of the BMAds and WAT adipocytes. 580 
10- An optimal shaking should provide the appropriate diffusion of the collagenase with the581 
whole tissue fragments while mixing the fatty acids with BSA, and yet should also avoid 582 
BMAd lysis. This shaking can modulate the digestion duration and can also be adapted 583 
according to the samples. As a general rule, shaking force should be highest at the 584 
beginning and reduced with time. Incubation time can vary between 15 and 45 minutes. 585 
11- Digestion occurs when increased turbidity appears. The medium becomes more and more586 
opaque because of BMAds which, once released, float at the surface (especially evident587 
once the tube is no longer being shaken). This step should be continuously monitored and588 
stopped when cell release from bone pieces seems reduced. Besides, the digestion must be589 
stopped when large amounts of lipids are released (i.e., oil appearance in the suspension590 
meaning that adipocytes burst).591 
12- The cell pellet contains BMSCs, which can be harvested at this step. After removing the592 
adipocytes, the remaining buffer with collagenase is aspirated. In a sterile hood, pellet is 593 
resuspended in red blood cell lysis buffer according to the manufacturer’s instructions: 594 
add 1ml of buffer, vigorously pipette to mix, let sit for 1 min, add 15 ml of KRH buffer 595 
(without BSA), pipette to mix. Then, split cell resuspension into two 14 mL falcon tubes and 596 
centrifuge at 300 g for 10 minutes prior to remove the supernatant. Then the pellet is 597 
resuspended in appropriate culture medium as described in the BMSC section (5.2.3). 598 
13- Even after cell dissociation with collagenase and separation of adipocytes by flotation,599 
some contaminant cells can remain attached to adipocytes. Thus, to purify adipocytes, it is 600 
important to wash and centrifuge the adipocyte suspension to pellet contaminant cells. 601 
14- BMAds are fragile and can burst during the washing steps so we recommend doing this602 
step as quickly and gently as possible. 603 
15- For Western blots or proteomic analyses, BSA must be removed to allow a correct protein604 
quantification of the samples. To do so, it is important to wash twice with PBS. 605 
16- If using a pipette, it is recommended to cut the tip using a scalpel to increase the bore size606 
of the pipette tip; this prevents shear stress and lysis of the BMAds. 607 
17- If BMAds are to be used only for downstream molecular analysis, it can be advised to store608 
the tube on ice to facilitate formation of the floating adipocyte layer, to use ice-cold 609 
washing buffer to minimize any further molecular changes and to centrifuge at 4 ºC. In that 610 
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case, the use of glass pipettes to homogenize in the RNA extracting reagent is beneficial 611 
because this promotes BMAd lysis and prevents adherence of the cells to the pipette, 612 
thereby increasing yields. 613 
5.1.3 Freezing and storage of BMAd samples 614 
The isolated BMAds can then be frozen according to the future analyses18 as indicated in the 615 
overview in Table 4. Special attention should be paid to the cell volume to adapt the volume 616 
of RNA extraction reagent (about 1:6 or 1:10 v/v) and to remove lipids. As for adipocytes from 617 
WAT, excessive lipid can prevent efficient RNA isolation. Thus, following initial cell lysis, it 618 
is helpful to allow the homogenate to settle on ice, resulting in a formation of a floating lipid 619 
layer. This lipid layer can then be removed and discarded, to be replaced by a similar volume 620 
of RNA extraction reagent. 621 
For untargeted lipidomics, BMAds can be frozen in methanol to allow a better stability of 622 
lipids. For targeted lipidomics, the extraction buffer is different depending on lipid classes. 623 
Thus, we recommend freezing samples directly in the appropriate extraction buffer. In other 624 
cases, BMAds can be frozen without extraction buffer but under nitrogen gas to prevent the 625 
oxidation of lipids. 626 
Notes: 627 
18- We recommend freezing a known volume of adipocytes in liquid nitrogen and keeping628 
samples at -80°C until use. When subsequent analyses are already planned, samples can be 629 
stored in specific media for better stability. 630 
5.1.4 Approaches to check purity and viability 631 
One issue with BMAd isolation is that non-BMAd populations may contaminate the layer of 632 
floating cells. As an example, human BMAds can have direct interactions with osteoclast 633 
precursors (62). Considering that macrophages are contaminants of isolated WAT adipocytes, 634 
other surrounding cells (e.g. BMSCs, endothelial cells, hematopoietic or immune cells) may 635 
remain attached to the floating BMAds. In addition, the evaluation of BMAd viability may be 636 
beneficial to discard cell alteration from the isolation procedure or for subsequent functional 637 
analysis. 638 
Evaluation of cell purity 639 
Immunofluorescence (IF) imaging is suitable to check both the morphology preservation 640 
following isolation and the size of BMAds, as well as potential contaminants. For good IF 641 
imaging it is better to embed BMAds in a matrix of fibrin gel (53). BMAds should contain a 642 
large lipid droplet filled with lipids, which can be stained using a fluorescent dye for neutral 643 
lipids such as BODIPY or LipidTox (Figure 5A), or the lipid-droplet marker Perilipin 1 644 
(PLIN1)(53, 63). Nuclear staining (using DAPI, Topro 3 or Hoechst) can inform on the 645 
presence of contaminant cells that could remain attached to BMAds (Figure 5B) (53, 64). 646 
Though not yet reported for human BMAds, the presence of specific markers such as CD45 for 647 
leukocytes and CD11b for myeloid cells has already been performed for mouse isolated 648 
BMAds using immunostaining to discard monocyte or macrophage contaminants (69). 649 
Alternatively, flow cytometry analysis following immunolabeling for markers of endothelial 650 
cells (CD31), stromal cells (CD105, CD90, CD24) has also been reported to validate the purity 651 
of human BMAds (70). 652 
BMAd purity is usually assessed by analyzing the expression of typical transcripts. 653 
Adiponectin (ADIPOQ), PPARg (PPARG), leptin (LEP) (69)  and PLIN1 (63) are used as 654 
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classical adipocyte markers. Other genes such as integrin alpha-5 (ITGA5), CD11B (encoded 655 
by ITGAM) and CD45 (encoded by PTPRC) have also been used, respectively, as markers of 656 
stromal cells (both for BMSCs and stromal vascular cells within WAT), leukocytes and other 657 
hematopoietic cells (51, 65). Based on the specifics of the conducted study, other markers for 658 
osteoblasts (e.g. RUNX2, Osteocalcin (62)) and for osteoclasts (TRAcP, Cathepsin K) can also 659 
be helpful to test cell purity. 660 
Evaluation of cell viability 661 
Based on previous studies investigating functional assays on BMAds (e.g. lipolysis) (53), 662 
metabolic studies require at least 50 µl suspension (around 50,000 cells) per condition and 663 
several experimental conditions (with and without pharmacological agents) are needed. 664 
However, the number of BMAds at the end of the purification process is generally limited 665 
and they are very fragile. Of note, other functional tests with isolated BMAds have already 666 
been performed following a 24h culture in various media (62, 63) or ceiling culture (54, 65), 667 
yet the impact of this subculture has not been clearly assessed. Therefore, it should be 668 
emphasized that these functional metabolic assays are difficult to set up and do not seem 669 
appropriate to rapidly check the viability of BMAds. Other developments of functional tests 670 
are thus to be pursued based on our growing knowledge of BMAd metabolism. 671 
5.2 Isolation and culture of BMSCs 672 
Within our working group, we reviewed two protocols for the isolation of BMSCs and 673 
BMAd-enriched fraction and validation of the purity of BMSCs obtained by BM aspirates 674 
from iliac crest or femoral head (55) (Table 2). Based on the source of BM aspirate, the yield 675 
of isolated BMSCs can differ (BM aspirate under local anesthesia vs BM aspirate taken 676 
during an orthopedic surgery procedure). In the following paragraphs, we describe a general 677 
protocol accompanied with the notes to highlight the critical steps and remarks which need to 678 
be considered during isolation. 679 
5.2.1 Isolation and transports 680 
BMSCs are isolated from BM of “healthy volunteers” (non-relevant diagnosis prior to surgery), 681 
from hematological patients at the iliac crest, or from orthopedic patients upon gentle washing 682 
of the femoral head (obtained and fragmented into pieces during hip replacement surgery) 683 
(Figures 4B and 4D). An aliquot of one ml of BM diluted with heparin can be centrifuged 684 
2,000 g, 10 min at 4°C to preserve BM plasma. After centrifugation, the supernatant (BM 685 
plasma) is transferred to a new tube and frozen at -80°C for subsequent analyses. 686 
BM aspirates are obtained by aspiration of 5-10 mL from the iliac crest after infiltration of the 687 
area with local anesthetic (lidocaine, 10 mg/mL), in a 20 mL syringe and mixed 1:1 with basal 688 
media containing heparin (100 U/mL) or EDTA (1 mM)1,2. 689 
After the isolation of the BM aspirate, the samples are transferred to a tube prepared with buffer 690 
containing anticoagulant and directly processed for isolation of BMSCs and BMAd-enriched 691 
fraction. The BM samples should be processed within a couple of hours, otherwise the viability 692 
of the cells can be compromised3. 693 
Notes: 694 
1- We do not observe a huge difference between heparin or EDTA as a source of anticoagulant695 
in the buffer for transport of BM aspirates regarding the yield and viability of isolated 696 
BMSCs. Similar results are obtained by collecting BM aspirates into commercial EDTA 697 
tubes or by using 1 mM of EDTA (replacing Heparin) into PBS. 698 
2- Before the procedure, Minimum Essential Medium (MEM) is prepared with heparin (100699 
U/ml) or with 1 mM EDTA and kept at 4°C. 700 
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3- The BM samples should be ideally transferred at room temperature and processed within701 
two hours. The transport duration and temperature should be recorded, as described702 
previously.703 
5.2.2 General procedure for BMSC and BMAd-enriched fraction isolation 704 
Reagents & Equipment: 705 
• Lymphoprep (StemCell, Scintila) (stored at RT, protected from a light)706 
• OR Ficol (Ficoll-PaqueTM PLUS (#17-1440-03, GE Healthcare)707 
• MEM (Invitrogen cat.no. 04193013M, stored at 4°C)708 
• MEM + 10 % Foetal Bovine Serum (FBS) + 1 % Penicilin/Streptamycin (stored at 4°C)709 
• Human Fibroblast Growth Factor (FGF)-2 (R&D system, # 233-FB-010) to add directly to710 
the medium at 1 ng/mL (optional) 711 
• Heparin (1,000 U/ml; stored at 4°C)712 
• Sterile filter (0.2 μM)713 
• 10 ml syringe714 
• Basket filter 100 μM715 
• Kwill or Falcon plastic tubes716 
• Small disposable needles717 
• Pasteur pipette718 
• Centrifuge with cooling and setting for non-break spinning719 
General protocol (Figure 4): 720 
• Dilute harvested BM aspirate 1:1 in PBS (with Ca and Mg), mix gently and immediately721 
divide into two 50 ml Falcon tubes4. 722 
• Add 10 ml Lymphoprep or 15 ml Ficoll by the kwill plastic tubes, which is placed at the 723 
bottom of the tube in order to create a gradient for the separation5.724 
• To obtain a floating BMAd-enriched fraction centrifuge samples at 1,050 g for 25-30 minutes725 
at RT without brake. For BMSCs, centrifuge samples at 300g 30 min at RT without brake. 726 
After centrifugation, collect the BMAd-enriched fraction on the top by a pipette (Figures 4C 727 
and 3) and follow the steps of washing and harvest in appropriate buffer depending on the 728 
subsequent analyses6,7. 729 
• For the mononuclear cell component containing the BMSC fraction, isolate the buffy coat730 
with a Pasteur pipette and transfer to the prepared 50 ml Falcon tube with preheated MEM 731 
medium. The buffy coats from both tubes are combined8. Higher BMSC yield can be obtained 732 
by also recovering the “serum” fraction above the buffy coat and below the floating BMAd-733 
enriched fraction, which contains less cells but relatively enriched in BMSCs. 734 
• Centrifuge tube at 1,050g for BMAds or at 300g for BMSCs for 10 min. Aspirate supernatant,735 
disperse cell pellet in fresh complete medium (~ 20 ml), count the cells and seed them for in 736 
vitro cultivation9. 737 
Notes: 738 
4- Before the gradient separation (by Lymphoprep or Ficoll), the BM sample is filtered with a739 
cell strainer (100 μm) to remove big clumps that can cause disturbances in the gradient. We 740 
apply a sterile plunger the filter to break the small aggregates and cell clusters. 741 
5- Lymphoprep or Ficoll are aspirated from the bottle with a small disposable needle, which742 
is changed to the kwill plastic needle appropriate for making the gradient. 743 
6- BMAd-enriched fraction is washed 2-3 times with PBS/1%BSA and then aliquoted for RNA744 
and protein sample by preservation in Trizol or protein lysis buffer, respectively, and stored 745 
at -80°C (more details in Table 4). Note that this fraction contains a very significant amount 746 
of contaminating hematopoietic and immune cells, but it is the only source of enriched 747 
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BMAd from iliac crest BM aspirates remaining from diagnostic procedures in 748 
hematological patients. Results associated to this fraction have to be interpreted within this 749 
context. 750 
7- The BMAd-enriched fraction can also be preserved for lipid storage. For this purpose, the751 
BMAd-enriched fraction is transferred to an Eppendorf tube, centrifuged at maximum speed 752 
for 5 minutes followed by collecting the lipid supernatant into a clean Eppendorf tube, flash 753 
freezing by submersion in liquid nitrogen and store at -80°C. Lipid extraction is performed 754 
at a subsequent step prior to further analysis (HPLC, lipidomics). 755 
8- The serum fraction above the buffy coat can also be collected, as it contains a significant756 
number of BMSCs. 757 
9- To improve cell growth, we add hFGF2 to the medium (at 1 ng/ml).758 
5.2.3 BMSC cultivation 759 
BMSCs are cultured at a density 1x105 cells/cm2 (1x106 cells per chamber slide)10 in MEM 760 
containing 10% fetal bovine serum (FBS, GIBCO) and antibiotics at 1% 761 
(penicillin/streptomycin) incubated at 5% CO2 and 37ᵒC followed by completely changing the 762 
medium once a week11, while passaging at 70-80% confluence. The cells from passage 0 are 763 
cryopreserved in freezing media containing FBS, MEM and DMSO12 (Table 4). For 764 
cryopreservation, cells in freezing media are immediately transferred into freezer at -80°C for 765 
24 hours before storing them in liquid nitrogen. 766 
Cultured cells are sub-cultured13 and further used for quality control tests (CFU-F, purity 767 
assessment, as described below (Section 5.2.5) and in previous literature (8) and subsequently 768 
studied in differentiation conditions when appropriate to induce adipogenesis, osteogenesis 769 
and/or chondrogenesis. Passage number should be recorded for all experiments13. 770 
Notes: 771 
10- We usually seed 10 million cells per T75 flask.772 
11- After 4-7 days the stromal cells have attached and started making colonies. Change773 
medium without disturbing or perturbing cells. Media can be switched to Super-MEM (10% 774 
FBS/1% pen/strep/glutamax/ nonessential amino acids/sodium pyruvate) to enrich the 775 
media for essential components needed for BMSC proliferation. 776 
12- There are several options to prepare freezing media e.g. 80% FBS, 10% MEM and 10%777 
DMSO (Table 4) or a variant recipe with 50 % MEM, 40 % FBS and 10 % DMSO. 778 
13- The cultured cells from passage 0 are usually sub-cultured 1:2 in order to expand for779 
further analyses and functional assays. Primary BMSCs are easily capable of passaging 780 
up to passage 6-7 but with each passage their capacity to proliferate and differentiate into 781 
different cell types is decreased, which affects their cellular and molecular properties. Also, 782 
they become more senescent as noticed when cells do not double within 4-5 days (71, 72). 783 
5.2.4 Sample storage 784 
Storage of BMSCs and BMAd-enriched samples depends on the purpose of the intended 785 
analyses (more details in Table 4). The stability of RNA or protein samples is superior when 786 
the samples are processed completely, rather than storing them in RNA or protein lysis buffer 787 
as specified in Table 4. The storage of BMSCs is more stable in liquid nitrogen compared to -788 
80°C. 789 
5.2.5 Qualyt controls 790 
There are several methods available to check the quality of isolated BMSC samples (as detailed 791 
in (8). Representative pictures of validated methods are depicted in Figures 6 and 7. 792 
Cell viability 793 
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The cell viability of isolated BMSCs can be verified by Trypan blue staining or by flow 794 
cytometry using 7-AAD staining (7- amino-actinomycin D; marker of dead cells) or Live/dead 795 
viability assay (73). 796 
Purity (hematopoietic, endothelial cell contamination) 797 
The purity of BMSCs can be checked by flow cytometry using CD markers for BMSCs (e.g. 798 
CD73, CD271, CD146, CD90, CD105), hematopoietic cells (e.g. CD45 neg), erythroid cells 799 
(e.g. CD235a neg) and monocytes/macrophages (e.g. CD14 neg, CD16 neg) (Figure 6 for 800 
representative dot plots for BMSC purity) (56, 59-61). 801 
CFU-F assay 802 
In order to test stem cell potency of isolated BMSCs (Figure 7A), we perform a CFU-F assay, 803 
i.e. capability of stem/progenitor cells to form colonies. We seed around 1 million isolated804 
BMSC cells in T25 flask and count number of colonies grown after 14 days. CFU-F assays are 805 
done through dilution of the test BMSC population and counting at day 14 after fixation and 806 
staining with either methylene blue or crystal violet (Figure 7B) (56, 59-61). 807 
Bi/tri-lineage differentiation assay 808 
To test differentiation potential of isolated BMSCs (70, 74), we seed and culture the cells in 809 
the conditions to differentiate into osteoblast (bone forming cells), adipocyte (BMAT forming 810 
cells), chondrocyte (cartilage forming cells) (Figure 7C-E). Each of these differentiation 811 
protocols can vary among different laboratories (8). For evaluation of osteoblast differentiation, 812 
we perform alkaline phosphatase (ALP) activity assay, Alizarin/ALP staining, gene expression 813 
of osteoblast genes (e.g. RUNX2, Osteocalcin (BGLAP), ALPL) ; for adipocyte differentiation 814 
these are Oil Red O or Nile Red staining, gene expression of adipocyte genes (PPARG, LPL, 815 
ADIPOQ, LEP), and for chondrocyte differentiation these are Alcian Blue staining, gene 816 
expression of chondrocyte genes (e.g. SOX9, COL2A1, ACAN) are evaluated (56, 59-61, 70, 817 
74). 818 
For the purpose of biobanking it is important to keep all necessary information related to the 819 
quality of BMSC samples. However, additional comparative studies are still needed to define 820 
the crucial parameters that influence BMSC quality, and which therefore are needed for 821 
interpreting the analyses of biobank samples. 822 
6 BMAS strategy to harmonize BMA-related biobanking and future perspectives 823 
Increased numbers of BMA-related publications in recent years using different sources of 824 
BMAT raised important questions about how to compare and reproduce the data in such a 825 
young and dynamic field. This raises an opportunity to create BMA biobanks that can provide 826 
material for other researchers and generate improved harmonization in future studies. 827 
Therefore, a standard protocol would be preferred to allow comparison of samples obtained 828 
from different institutions with specifications of critical points, which have been raised in this 829 
position paper based on the evaluation of the current literature. 830 
While isolation protocols and collections for BMSCs have been proposed from various 831 
laboratories and private companies for long standing, those relative to BMAds are more recent 832 
and heterogenous. We currently validated three protocols from which we generated a general 833 
procedure to isolate BMAds using collagenase. Yet, it can be acknowledged that this digestion 834 
step (i.e. type of collagenase, duration of collagenase treatment, etc.) has to be further 835 
standardized and its impact on adipocyte selection, viability and functionality further 836 
characterized. When pure BMAd suspension is required or if the BMAds are to be compared 837 
with WAT adipocytes, the use of collagenase is recommended to prevent contamination from 838 
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other cell types and to ensure that differences between adipocyte isolation procedures is not a 839 
confounding factor (65). 840 
As technical developments in transcriptomics and other -omics approaches performed in 841 
various other tissues could be relevant for future BMAd analyses, we provide the following 842 
suggestions regarding next generation sequencing approaches based on preliminary and often 843 
unpublished results from different laboratories belonging to the consortium. Indeed, several 844 
factors have been determined as critical for single cell RNA sequencing (scRNA-seq) and other 845 
-omics approaches. We also suggest to minimize as much as possible manipulation of the cell846 
prior to any -omics or transcriptomic approach. Indeed, very recent studies suggest that routine 847 
steps such as collagenase digestion can have a detrimental effect on the cell’s transcriptome for 848 
all single cell analyses and other omics approaches. If to be used, the time of collagenase 849 
treatment or other digestion enzymes should be as short as possible as it has been shown to 850 
drastically affect the transcriptome, resulting in that the most important gene signature is the 851 
digestion itself (75). 852 
Furthermore, a recent study determined that flash freezing (cryopreservation) of cells from BM 853 
aspirates prior to scRNA-seq does not affect the transcriptome (76). By doing so, multiple BM 854 
samples can be analyzed simultaneously, which would drastically reduce the batch effect that 855 
is often visible for single cell RNA-sequencing experiments. Since currently available scRNA-856 
seq analyses are thus far challenging (77), the compatibility of cryopreservation with single 857 
nuclei RNA-seq could constitute a very interesting approach to determine and better 858 
characterize the BMAT transcriptional landscape. Indeed, it is today impossible to process an 859 
entire adipocyte by standard scRNA-seq, since current technologies use pure oil to create the 860 
encapsulation droplets. Partial adipocyte lysis, which is hard to avoid due to their natural 861 
fragility, prevents the formation of the droplet emulsion and ruins the chip for further use. 862 
However, nuclei extraction from BMAds is still very challenging and current procedures still 863 
need to be improved. Altogether, the WG suggests to limit the use of collagenase digestion as 864 
much as possible while collecting BMAT for these specific transcriptomic analyses since an 865 
absolute cell purity is not required and such a digestion step could interfere with subsequent 866 
analyses. Finally, critical differences between our protocols should be further discussed and 867 
validated (e.g. precise requirements and specifications for clinical sample isolation and 868 
transportation) or improved (easier and standardized assays to assess the quality of samples, 869 
increased yield of isolated materials) for harmonization purposes. Meanwhile our current work 870 
paves the way for BMAT biobanking perspectives and next generation sequencing. We thus 871 
strongly encourage future publications to provide a detailed description of patient 872 
characteristics, BMA source and sampling, isolation procedures and validity tests to enhance 873 
standardization in the field. 874 
Last but not least, we should pay attention to clinical/molecular data and the anonymization of 875 
participants` personal information as they are aimed to be shared among different institutes. At 876 
all times, the utmost care should be taken to deidentify the samples obtained from study 877 
participants (as discussed in section 2.2). The technological advancements to perform genetic 878 
analyses have advanced to such an extent that certain approaches, such as RNA sequencing 879 
and single cell sequencing can allow for identification of the individual. Therefore, there is a 880 
task at hand to create awareness among researchers to minimize risks of deidentification. 881 
Future perspectives 882 
Although we are still several steps away from achieving this, harmonizing protocols globally 883 
would greatly enhance the quality and interpretation of BMA-associated outcomes and yield 884 
increased impact in the field. A longer-term goal of this WG is to establish a common protocol 885 
39 
or minimal conditions that everyone could use. In an attempt to achieve this, one action of the 886 
WG will be to setup a study in which the same material will be processed in different labs, 887 
using an identical protocol followed by careful evaluation of the outcomes. 888 
It is important to emphasize that at the beginning of creating a BMA biobank one needs to think 889 
about preparation of broad consent for future research, which may help to facilitate 890 
harmonization as well and, as it is ethically valid, this should be recommended for biobank 891 
research (9). In addition, harmonizing sample collection and storage will facilitate medical 892 
ethical boards of institutes of collaborating universities about the synchronous sample 893 
characteristics of incoming or outgoing samples in case of international studies. One of the 894 
other things that the BMAS WG on Biobanking has in mind is to develop a global material 895 
transfer agreement (GMTA) that would allow for easier acceptance and transport of BMA-896 
related samples between institutes across the globe. 897 
Altogether, this position paper should create awareness and facilitate scientists involved in 898 
BMA that plan to or continue studies in which collection, storage and analysis of BMA-899 
related samples are involved. 900 
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Table 1: Issues to be considered in patient information and informed consent forms 973 
Item Patient information form (PIF) 
(presented to the participant before 
donation) 
Informed consent form 
(signed by the participant, after considering 




1. What is the purpose of the study?
- Background information and simple
description of the study (broad or
specific to BMA research)
- Clear description of goals and
expected results will help to increase
the participation rates
- Study is approved by Research Ethics
Committee / Institutional Review
Board
2. What sample material will be collected?
- BM sample (tissues/cells)
- Reference samples (eg. subcutaneous
fat, blood)
3. How it will be collected?
- Sampling procedure
(surgery/biopsy/aspirate)
- Risks and disadvantages related to BM
sampling
4. What the sample will be used for?
- Broad purpose (unspecified projects) or
BMA-specific purpose
- General risks related to the sample
donation and storage (eg. storage of
genetic information)
Donor has had enough time to familiarize 
him/herself to the information provided in 
the PIF 
Donor has had a possibility to ask questions 
after considering the information in the PIF 
Donor understands the risks and benefits of 
participation 
Risks 
- General risks of sample donation
- BMA-specific risks (e.g. risks related
to the BM sampling procedure), blood
sampling, or surgery.
Benefits 
- No direct health benefits or financial
benefits
- Indirect benefits via promoting BMA-
related research (and e.g.  development
of novel therapies in the future)
Donor provides information about his/her 
clinical condition 
- Current diseases and treatments
- Past diseases and treatments
- Age, metabolic status and lifestyle
habits (according to the study)
b. Sample and
data storage
5. Who can access the biological samples
and the data obtained?
- Only approved research studies (with
ethical approval) may have access to
the samples
- Tissue/cells that is left over from this
study will be stored for future research
to learn more about BMA
Donor allows the use of 1) biological 
samples and 2) the data resulting from the 
research using these samples. 
- The permission to store unused samples




6. What procedures will be used to protect
the privacy and confidentiality of the data?
- Explain what personal data is collected
and how the data is anonymized
- Sample material (and the data resulting
from these samples) cannot be traced
back to any of the person-related data
Donor understands 1) what data is collected 
and 2) how the data will be secured (Data 
Privacy Statement). 
• Donor understands he/she will not have later 
access to his/her own data as all data is 
deidentified. 
d. Withdrawal 7. How to withdraw from the study?
- Participation is always voluntary
Sample is donated to biobank voluntarily. 
45 
- Provide contact information for
withdrawal from the study (email,
phone number, website)
- Explain how the samples and
associated data will be destroyed after
withdrawal: new data cannot be
obtained and that existing data will be
maintained in a non-identifiable form
Donor can withdraw from the study later at 
any time and without any reason.  
- Explain how the withdrawal should be
signaled to the researchers (eg. email,
letter, phone call)
974 
Table 2: Summary of critical steps for BMAd and BMSC isolation to highlight differences 975 
between protocols 976 
Different protocols have been set up to isolate BMAds (from 3 institutes: EDIN, TOUL, 977 
LILL) or BMSCs (from 2 institutes: LAUS, PRAG). Differences related to biological 978 
material, digestion and washing parameters are highlighted. 979 
Main steps EDIN TOUL LILL LAUS PRAG 
Material 































































Abbreviations referring to institute cities of members within BMAS Biobanking WG. EDIN: 980 
Edinburgh (WC); TOUL: Toulouse (CA); LILL: Lille (SL), LAUS: Lausanne (ON); PRAG: 981 
Prague (MT). 982 
983 
Table 3: Composition of buffers used for sample transportation 984 
Five different buffers have been used for sample transportation: Krebs Ringer Bicarbonate 985 
HEPES buffer (KRBH), Krebs Ringer HEPES (KRH) and Dulbecco’s Modified Eagle’s 986 
Medium (DMEM, Dutscher, L0064). The concentrations of the different components are 987 
indicated in mM, except for BSA. 988 
EDIN TOUL LILL LAUS PRAG 




MgCl2; 6H2O N/A 0,5  N/A N/A N/A 
MgSO4 0,6 N/A  0.8 N/A 0.8 
KCl 2 4,6  5.4 2.7 5.3 
NaCl 120 120  110 137 117.24 





























250 UI/mL 0.2 to 0.3 
UI/mL 
1 UI/ml - 
Digestion time 45min Max. 20 
min 
15-30 min 45 min -1h - 
Washing 








PBS / 1% 
BSA 
PBS / 1% 
BSA 
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NaH2PO4 (anhydrous) N/A 1,5  1 N/A 1 
KH2PO4 1 N/A  N/A 1.8 N/A 
CaCl2; 2H2O 1 N/A  1.8 N/A 1.8 
D-Glucose 5,5 10  5.5 N/A 5.5 
NaHCO3 N/A 150  44 N/A 26.2 
HEPES 81,6 10  N/A N/A N/A 
Bovine Serum Albumin 
(BSA) 
1% 0.5%  N/A 0 N/A 
Abbreviations referring to institute cities of members within BMAS Biobanking WG. EDIN: 989 
Edinburgh (WC); TOUL: Toulouse (CA); LILL: Lille (SL); LAUS: Lausanne (ON); PRAG: 990 
Prague (MT). 991 
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Table 4: Recommended storage of isolated BMSC and BMAd samples 993 
Storage of the samples BMSCs BMAds 
Cell cryopreservation One million cells in freezing 
media (per vial: 80% FBS, 
10% DMSO, 10% MEM or 
50% MEM, 40% FBS, 10% 
DMSO) in liquid nitrogen). 
Impossible to keep 
viable frozen BMAds. 
Frozen isolated BMAds 
can be snap-frozen in 
liquid nitrogen and 
stored at least at-80°C 
for further analyses. 
RNA In Trizol (or similar) at -80°C 
Protein In protein lysis buffer at -80°C 
Lipids Flash freezing in liquid nitrogen within 4 hours after 
surgery. 
Store at -80°C 
994 
Figure legends 995 
 996 
Figure 1: Workflow for BMA-related research 997 
998 
Figure 2: Schematic figure showing the locations from which BMAT is obtained 999 
Locations from which BMAT is obtained, heterogeneity in tissues (e. g. more fatty vs less fatty) 1000 
and collected fractions. 1001 
1002 
Figure 3: Processing of the BMAd-enriched fraction without digestion step 1003 
(A) Samples are received from surgeries into their transport buffer. The adipocyte-enriched1004 
layer is harvested, filtered and washed. (B) Several examples of BMAd-enriched fractions after 1005 
washing are shown. 1006 
1007 
Figure 4:  Schematic protocol for isolation of BMAds and BMSCs 1008 
(A) Strategy to recover BMAds and BMSCs depending of the tissue source. (B) Wash and1009 
mince the selected tissue. (C) Digestion strategy using collagenase digestion to increase the 1010 
release and the purity of BMAds. Some encountered challenges are shown such as the lysis (1) 1011 
and low yield (2) of BMAds. At the end of the process pure BMAds are obtained. (D) BMSCs 1012 
isolation with tubes showing the variation observed between samples. BMSCs are obtained 1013 
after centrifugation of the serum fraction and the BSMC-enriched fraction. 1014 
1015 
Figure 5: Histological images demonstrating the purity of the BMAds 1016 
(A) BMAds were stained with Hoechst and LipidTox DeepRed. Stromal-vascular cells (SVCs)1017 
were included as a negative control for LipidTox staining. Stained cells were then analysed 1018 
using a Nexcelom Vision Cellometer. Adipocyte images confirm that all nuclei are associated 1019 
with unilocular lipid droplets and there are no lipid-free nuclei, suggesting an absence of 1020 
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contaminating non-adipose cell types. Analysis of the SVC fraction confirms that the LipidTox 1021 
signal is dependent on the presence of lipid droplets. Scale bar represents 100 μm. (B) BMAds 1022 
were stained with BODIPY and Topro 3 to verify by IF the integrity of BMAds (BODIPY 1023 
staining) and the purity of the adipocyte suspension. Nucleus staining show the presence of 1024 
contaminant cells attached to adipocytes (red squares). 1025 
1026 
Figure 6: BMSC purity assessment by flow cytometry 1027 
Screening of stem cell surface markers expression (positive for CD44, CD73, CD90, CD146, 1028 
CD140b, CD105, and negative for CD45 and CD14) measured by flow cytometry in primary 1029 
human BMSCs isolated from iliac crest cultured in vitro at passage p0. 1030 
1031 
Figure 7: In vitro evaluation of BMSC quality (BMSC culture, CFU-C, tri-differentiation) 1032 
(A) Representative picture of spindle-like shape cells in In vitro culture of human BMSCs. (B)1033 
CFU-F of BMSCs after 14 days in vitro culture visualized by Violet Blue in a petri dish. (C) 1034 
Alizarin staining of mineralized matrix in 10 days osteoblast (OB) culture differentiated from 1035 
primary BMSCs. (D) Oil Red O staining of neutral lipids in a 10 days adipocyte (AD) culture 1036 
differentiated from primary BMSCs. (E) Alcian Blue staining of a 21 days chondrocyte (CH) 1037 
culture differentiated from BMSCs. Scale bar represents 200 μm in all the pictures. 1038 
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